Wall Street analysts expect Compugen Ltd. (NASDAQ:CGEN) to post ($0.11) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Compugen’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.12). Compugen posted earnings of ($0.16) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 31.3%. The firm is scheduled to issue its next earnings report on Tuesday, February 25th.
According to Zacks, analysts expect that Compugen will report full year earnings of ($0.44) per share for the current fiscal year, with EPS estimates ranging from ($0.45) to ($0.43). For the next financial year, analysts expect that the firm will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.43) to ($0.37). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Compugen.
Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Monday, November 11th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01.
CGEN has been the topic of several recent analyst reports. Cantor Fitzgerald initiated coverage on Compugen in a report on Wednesday, January 15th. They issued an “overweight” rating and a $10.00 price target on the stock. Zacks Investment Research lowered Compugen from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. ValuEngine lowered Compugen from a “hold” rating to a “sell” rating in a research report on Friday, January 3rd. Finally, BidaskClub upgraded Compugen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $8.42.
CGEN traded up $0.04 during trading on Monday, reaching $6.12. 297,435 shares of the company were exchanged, compared to its average volume of 251,933. The company’s 50-day moving average is $5.85 and its two-hundred day moving average is $4.59. The company has a market cap of $313.90 million, a price-to-earnings ratio of -12.24 and a beta of 2.74. The company has a quick ratio of 7.19, a current ratio of 7.19 and a debt-to-equity ratio of 0.07. Compugen has a 12-month low of $2.73 and a 12-month high of $6.45.
Several institutional investors have recently made changes to their positions in CGEN. Wells Fargo & Company MN grew its position in Compugen by 424.5% during the 2nd quarter. Wells Fargo & Company MN now owns 7,526 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 6,091 shares during the last quarter. LPL Financial LLC bought a new stake in shares of Compugen in the 2nd quarter worth approximately $43,000. Jane Street Group LLC grew its position in shares of Compugen by 20.5% in the 2nd quarter. Jane Street Group LLC now owns 65,721 shares of the biotechnology company’s stock worth $252,000 after buying an additional 11,192 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in shares of Compugen in the 2nd quarter worth approximately $45,000. Finally, Janney Montgomery Scott LLC bought a new stake in shares of Compugen in the 3rd quarter worth approximately $68,000. Hedge funds and other institutional investors own 42.20% of the company’s stock.
Compugen Company Profile
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Article: What is the accumulation/distribution indicator?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.